

Supplementary Table 3. Disease control rates (DCR) recorded (partial response or stable disease) according to RECIST during second-line Molecular Targeted Therapy (MTT) in patients with PanNENs.

Patient Characteristics (n=28)		DCR in Everolimus group	DCR in Sunitinib group	P-value
		N=11	N=17	
Gender	Male	5/8	8/11	0.636
	Female	2/3	5/6	0.999
Age mean (SD)		54.9 (17.2)	59.2 (14.7)	0.490
Inheritance	Sporadic	5/9	11/15	0.371
	Familial (MEN1)	2/2	2/2	-
Liver Tumour Load	No liver metastases	1/1	-	-
	<5 unilobar liver metastases	1/1	5/5	-
	5-10 unilobar liver metastases and/or bilobar liver metastases	-	-	-
	>10 liver metastases or diffuse liver metastases	5/9	8/12	0.673
Ki67 Group	G1 (ki67 <3%)	1/2	2/3	0.999
	G2 (ki67 3-20%)	6/9	9/12	0.676
	G3 (ki67 >20%)	-	-	-
Secretory status	Yes	1/2	3/5	0.999
	No	6/9	10/12	0.375
Prior Surgery	Yes	6/9	7/9	0.599
	No	1/2	6/8	0.999
SRS or Ga68-PET	Positive	6/9	11/15	0.728
	Negative	1/1	2/2	-
	Unknown	0/1	-	-
FDG-PET	FDG-PET positive	0/1	1/1	-
	FDG-PET negative	1/3	3/3	-
	Unknown	6/7	9/13	-
Previous treatment	SSA or naive	3/4	9/10	0.505
	Pre-treated with chemotherapy	4/7	4/7	0.999
Charlson Comorbidity Index	0	4/8	10/12	0.161
	1	3/3	2/4	-
	2	-	1/1	-
	3	-	-	-

DCR: Disease Control Rate; MTT: Molecular Targeted Therapy; SD: Standard Deviation; SRS: somatostatin receptor scintigraphy; Ga: Gallium; FDG-PET: fluoro-deoxyglucose positron emission tomography

Pearson chi-square test and Fisher's exact test as well as student's t-test were conducted as appropriate.